MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
37.90
+1.00
+2.71%
Opening 10:10 07/25 EDT
OPEN
37.22
PREV CLOSE
36.90
HIGH
38.08
LOW
37.00
VOLUME
15.82K
TURNOVER
0
52 WEEK HIGH
38.08
52 WEEK LOW
13.36
MARKET CAP
1.04B
P/E (TTM)
-6.1837
1D
5D
1M
3M
1Y
5Y
1D
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc. The company is a clinical-stage biotechnology company focused on delivering immunology therapeutics. AnaptyBio has a pipeline of checkpoint agonists, including rosnilimab in development for rheumatoid arthritis.
Benzinga · 2d ago
AnaptysBio Initiated at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Initiates Coverage On AnaptysBio with Buy Rating, Announces Price Target of $55
Benzinga · 3d ago
AnaptysBio’s Promising Pipeline and Rosnilimab’s Best-in-Class Potential Justify Buy Rating
TipRanks · 3d ago
ANAPTYSBIO INC <ANAB.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $55
Reuters · 3d ago
Weekly Report: what happened at ANAB last week (0715-0719)?
Weekly Report · 3d ago
U.S. RESEARCH ROUNDUP-Align Technology, McKesson, Schneider National
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Align Technology, McKesson, and Schneider National have lower targets. Abercrombie & Fitch, American Airlines and Amazon.com among the companies with new targets cut.
Reuters · 3d ago
JP Morgan Upgrades AnaptysBio (ANAB)
NASDAQ · 5d ago
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.